Dedicated to Healthcare Professionals Worldwide
November 4 – 5, 2021
Thursday, November 4th
Day 1 – Conference Opens at 10:00 a.m. EST
Day 1 – Day 1 – Concludes at 4:00 p.m. EST
Friday, November 5th
Day 2 – Conference Opens at 10:00 a.m. EST
Day 2 – Conference Concludes at 4:00 p.m. EST
Please Note: Keynote Speaker Dates and Time May Change ~ Please Check Back For Final Updates. Thank You.
Welcome To the 9th Annual International
Conference and Health EXPO
Meet Our Keynote Speakers
Stuart B. Johnson, MD, FIDSA, DTM&H
Conference Co-Chair & Keynote Speaker
Dr. Johnson, MD, FIDSA, DTM&H Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus have involved the epidemiology pathogenesis and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Discussion Group II
Conference Co-Chair & Keynote Speaker
Dr. Feuerstadt, MD, FACG, AGAF is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research, and graduated Summa Cum Laude. Following the completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency, Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital seeing outpatients in his offices in Hamden & Milford, CT
Discussion Group II
Professor Simon M. Cutting, Ph. D.
Professor Cutting, Ph. D., School of Biological Sciences at the Royal Holloway University of London Professor Cutting is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus subtilis. After spending 7 years in the renowned laboratory of Professor Richard Losick at Harvard University Biological Laboratories (USA) he spent 3 years as an Assistant Professor at the University of Pennsylvania Medical School in Philadelphia. He returned to the UK in 1996 and since then has worked on developing bacterial spores as novel oral vaccines at the Royal Holloway, University of London.
Presentation Topic: “What Makes Us Susceptible to a C. difficile Infection?”
Dr. Petrosillo earned a degree of Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became a specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy. He is a fellow of the Pulmonary Vascular Research Institute and leader of the international task force for pulmonary hypertension associated with HIV, since 2007. He is a member of the Professional Affairs Subcommittee on Infectious Diseases and a member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy
Presentation Topic: “The Burden of Clostridioides difficile Infection In the COVID-19 Era.”
Dr. McGovern is VP, Medical Affairs of Seres. Dr. McGovern has over 25 years of experience in infectious diseases. Prior to joining Seres, she served as Medical Director in the Medical Affairs Division at AbbVie and helped to launch Viekera Pak for treatment of Hepatitis C virus (HCV) infection. At AbbVie, Dr. McGovern was a recipient of the 2015 President’s Award in recognition of the successful execution of 7 major publications in the New England Journal of Medicine, Lancet, and JAMA. As an academic clinician at Tufts Medical Center, she also authored more than 50 journal articles, editorials, and textbook chapters on HIV and HCV and was an Associate Editor of Clinical Infectious Diseases and a Deputy Editor at Up-To-Date.
Presentation Topic: “Results from ECOSPOR III, a Phase 3
Placebo-Controlled Trial of SER-109, an Investigational Microbiome Therapeutic to Reduce
Recurrence of Clostridioides difficile Infection.”
Florence Séjourné is the Chief Executive Officer of DA VOLTERRA, a Paris-based biotech company that develops innovative products for the protection of the microbiota from antibiotic residues for which the medical need is increasing. Its most advanced product, DAV132, is a novel and unique oral phase 2 stage-product designed to fight the damaging effects of antibiotics on the large intestine. Prior to joining Da Volterra in 2008, Florence spent 11 years co-founding and developing Genfit (Euronext GNFT), now a leading public European biotech company in the field of metabolic and inflammatory diseases with a particular focus on liver and GI (NASH). Florence has thus the experience of successful entrepreneurial adventures and the capacity to set up and lead a highly professional organization from early research drug discovery to late-stage clinical development and market access.
Florence was trained in France (Mines Paritech, Biotechnology Major) and holds an MS in Pharmaceutics & Bioengineering from the University of Illinois at Chicago.
Presentation Topic: “Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis.”
Dr. Haidegger received his MSc degrees from the Budapest University of Technology and Economics (BME) in Electrical Engineering and Biomedical Engineering, then PhD in medical robotics. Currently, he is associate professor at Óbuda University, serving as the director of the University Research and Innovation Center (EKIK), and as the technical lead of medical robotics research. Tamás is the co-founder of a university spin-off—HandInScan—focusing on objective hand hygiene control in the medical environment, member of the World Health Organization POPS group. He is a national delegate to the ISO TC299 standardization committee focusing on the safety and performance of medical robots and the ISO TC 304 working on hand hygiene and patient safety standards, furthermore, involved in the IEEE Global Initiative on Ethics of Autonomous and Intelligent Systems.
Presentation Topic: “Evidence-Based Hand Hygiene In the Post-COVID World.”
Mary Ruisi, M.D.
Dr. Ruisi, MD is the Vice President of Clinical Research at Vedanta Biosciences, Inc., a cutting edge biotechnology company whose goal is to harness the human microbiome for the treatment of different diseases and illness, such as recurrent C. difficile infection, inflammatory bowel disease, and food allergy. Dr .Ruisi received her Medical Degree at Mount Sinai School of Medicine in New York City, her residency in pediatrics at New York Presbyterian-Weill Cornell Medical Center, and her fellowship in pediatric hematology-oncology at Memorial Sloan Kettering Cancer Center. Dr. Ruisi is a physician biopharmaceutical expert in oncology and immuno-oncology Phase I-III clinical drug development. Her excellent track record in strategy, medicine, and science makes her a forefront leader in the development of Vedanta’s live biotherapeutic products.
Dr. Ruisi will be presenting on the topic of Vedanta’s work in this field and their subsequent pipeline programs.
Presentation Topic: “A Defined Bacterial Consortium – VE303”
Layla Ouldnouri represents her team of
Presentation Topic: “Bioluminescence of C. difficile Spores.”
Beth Guthmueller, is the Senior Clinical Research Scientist, Rebiotix Inc, a Ferring Company, joined Rebiotix in 2013, with over 25 years of experience in biologic and medical device clinical stage scientific research and clinical/preclinical study management. She was the first Senior Clinical Research Associate at Rebiotix and helped to initiate and manage each of the clinical studies conducted to date. As a passionate patient advocate, Beth is grateful for the opportunity to partner with the study site physicians, nurses, and coordinators who are dedicated to helping patients suffering from C. difficile infection. She is currently a Senior Clinical Research Scientist and is working to compile the study data for the FDA and to assist with the continued development of Rebiotix’s clinical research program.
Presentation Topic: “Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective studies”
Dr. Wilcox is the Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health, in England in the UK. He was Director of Infection Prevention, and Control, Doctor and Clinical Director of Pathology at LTHT. Dr. Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare-Associated Infection Committee and is a member of the HPA’s Program Board on Healthcare-Associated Infection & Antimicrobial Resistance. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents.
Presentation Topic: “Using a Gut Model to Predict Which Antibiotics are Associated With C. difficile Infection and Which Ones Best Treat a C. difficile Infection.”
Dr. Moïsi , Ph. D.. is the Vice President and Global Medical Franchise Lead, Tick-Borne Diseases and Enteric Vaccines at Pfizer where she oversees medical development and scientific affairs for Lyme disease, Tick-borne encephalitis (TBE), C. difficile and other enteric vaccines. Prior to her role, she was on secondment as Pfizer’s Medical Franchise Lead of Bacterial Pipeline Vaccines covering the C. difficile, Group B Strep and E. coli vaccine candidates. Jennifer Moïsi holds a PhD in International Health (Global Disease Epidemiology and Control), a Masters of Health Science (MHS) in Biostatistics and a Certificate in Vaccine Science and Policy from the Johns Hopkins Bloomberg School of Public Health, and a Diplôme d’Ingénieur from the École Polytechnique.
Presentation Topic: “Development of a Vaccine with the Potential to Prevent Clostridioides difficile Infection (CDI) .”
Larry Kociolek, MD
Moderator – Group Discussion I
‘Recent Developments in Diagnosis, Treatment, and Prevention of
C. difficile infection in Children.’
Dr. Kociolek, MD, is an Attending Physician at the Ann & Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, the Medical Director of Infection Prevention and Control at Lurie Children’s whereby he coordinates the surveillance for and prevention of infection-related adverse events and leads administrative efforts to optimize patient and healthcare worker safety. Broadly, Dr. Kociolek’s academic interests are focused on healthcare epidemiology, particularly pediatric Clostridioides difficile infection and infections caused by antibiotic-resistant organisms.
Panelist – Group Discussion I
Dr. Sandora , MD, MPH is an Associate Professor of Pediatrics at Harvard Medical School and an attending in pediatric infectious diseases at Boston Children’s Hospital, where he has served as the Hospital Epidemiologist and Medical Director of Infection Prevention and Control since 2005. Dr. Sandora’s research interests focus on healthcare-associated infections in children, including epidemiology and prevention of pediatric C. difficile infection. He is a co-author of the IDSA-SHEA Clinical Practice Guidelines for C. difficile infection in adults and children, as well as the SHEA Compendium of strategies to prevent C. difficile infections in acute care hospitals.
Panelist – Group Discussion I
Dr. Nicholson, MD, MPH, Assistant Professor of Pediatrics, Associate Program Director, Pediatric Gastroenterology, Hepatology and Nutrition Fellowship Program. Maribeth R. Nicholson, MD MPH, is an assistant professor of pediatric gastroenterology, hepatology and nutrition at Vanderbilt University Medical Center. a pediatrician, an epidemiologist.
Dr. Khanna, M.B.B.S., M.S., is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. His research and clinical interests include Epidemiology, Outcomes, and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations. He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program, and C. difficile related Clinical Trials at Mayo Clinic, Rochester, MN.
Presentation Topic: “Microbiome Therapeutics in 2021: Almost there for C difficile!“
Caterina Oneto, MD, & C. diff. Global Tele-Support Program, Co-Director Dr. Oneto, MD is a Clinical Instructor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine. Dr. Oneto is fluent in Spanish. She graduated with a degree in Medicine and Surgery from the Universidad de Valparaiso in Chile and completed her residency in Internal Medicine at Cabrini Medical Center, where she served also as Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. With expertise in endoscopy, colonoscopy, capsule endoscopy, liver, and pancreatic diseases,
Dr. Oneto’s special interests include IBD (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of Clostridioides difficile, and FMT (Fecal Microbiota Transplantation).
Presentation Topic: “Is this C. diff.? How IBS and IBD Complicate the Diagnosis and Management of Patients with a CDI.”
Ken Blount, Ph.D.
Dr. Blount, Ph.D., CSO Rebiotix Inc, a Ferring Company and VP Microbiome Research Ferring, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix,
Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a co-founder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a Ph.D. in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Presentation Topic: “Introduction to Microbiota and Microbiota Restoration for Recurrent C. diff infections”
David Bischoff is a C. diff. Survivor. Dave will share his journey.
Presentation Topic: A C. diff. infection; A life-changing journey.
Dr. Budree, MD is the Medical Director and the Head of Clinical Microbiome Science at Finch Therapeutics, a clinical-stage company dedicated to harnessing the microbiome to transform lives. Prior to Finch Therapeutics, Dr. Budree served as a Senior Clinical Research Fellow at the nonprofit OpenBiome. Dr. Budree is a pediatric gastroenterologist with post-doctoral research training from the Broad Institute of MIT and Harvard and Massachusetts General Hospital. He has published extensively on the microbiome and led pioneering microbiome transplantation research across a wide array of different disease areas at both OpenBiome and Finch Therapeutics.
Presentation Topic: “CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI”
Friday, November 5, 2021
10:00 a.m. – 4:00 p.m. EST
Curtis Donskey, MD
Dr. Donskey, MD, is an Infectious Disease physician at the Louis Stokes Cleveland VA Medical Center. He has served as hospital epidemiologist and Chair of the Infection Control Committee since 1999. His research focuses primarily on infection control of healthcare-associated pathogens, particularly Clostridioides difficile. He has conducted numerous studies examining the role of the environment in the spread of pathogens and identifying effective cleaning methods.
Presentation Topic: “Empowering Patients to Prevent a C. difficile Infection. “
Jordan Bastian, MPH, CIC
Jordan Bastian is a Senior Clinical and Scientific Affairs Specialist for CloroxPro and Clorox Healthcare and is committed to keeping communities healthy through infection prevention and control. In this role, he provides consultative services with technical expertise and develops practical tools for environmental disinfection. His background as an Infection Preventionist and expertise across the healthcare industry over the last nine years afford Jordan with valuable firsthand insights in public health, infection prevention and epidemiology. Most recently, Jordan was Public Health Officer at Boise State University where he instituted guidance for the University’s COVID-19 mitigation efforts and worked with state and federal agencies and community organizations on COVID-19 response strategies.
Presentation Topic: “Introducing a New Disinfection Technology Against C. diff.”
Kerrie Davies, Ph.D.
Dr. Davies, Ph. D., joined the University of Leeds as a Visiting Research Fellow in 2015. A researcher at Leeds Teaching Hospitals since 1998, and began Clinical Scientist training in 2004 becoming state registered in 2007, moving to Principal Clinical Scientist in 2016. Principal Clinical Scientist for the Healthcare-Associated Infections Research Group Scientific lead COMBACTE-CDI, EUCLID, EUCLID 2, ORCHID, LUCID. Clostridium difficile toxin detection methods and the UK Department of Health-funded multi-center study to determine the optimal methods for CDI diagnosis. This study changed the UK C. difficile laboratory diagnostic guidelines and has gone on to influence both the European (ESCMID) and US (SHEA) guidelines. Currently, I am a co-investigator and the scientific lead for work-packages 1 and 2 of COMBACTE-CDI, an Innovative Medicines Initiative (IMI2) Horizon2020 funded project to determine the burden of CDI across the whole of the healthcare economy in Europe.
Presentation Topic: “Key differences in diagnosis and patient populations between community and in-patient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).”
Dr. Garey, Pharm.D., M.S., is Chair of the Department of Clinical Sciences and Administration and Professor of Pharmacy Practice at the University of Houston College of Pharmacy in Houston, Texas. He also serves as Division Head, Experiential Therapeutics and Clinical Pharmacology. Additionally, he holds an academic appointment as Adjunct Associate Professor at the University of Texas School of Public Health in Houston. Dr. Garey is an active member of the Society of Infectious Diseases Pharmacists and the American Society of Health-Systems Pharmacists (ASHP). His research interests include antimicrobial stewardship activities to prevent and treat Clostridium difficile infection, surgical site infections, and systemic candidiasis.
Presentation Topic: “Ibezapolstat Update: Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect?”
Dr. Dubberke, Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University.
Presentation Topic: “Difficulties in CDI Diagnosis: Is PCR Alone Adequate.”
Dr. David Lyerly, Ph. D.
Dr. Lyerly, co-founder and Chief Science Officer of TECHLAB, Inc. Dr. Lyerly received his B.S. from UNC-Chapel Hill and his Ph.D. in microbiology/Immunology from Wake Forest Bowman Gray School of Medicine. He and Dr. Tracy Wilkins founded TECHLAB in 1989. TECHLAB focuses on innovative diagnostic solutions for C. difficile, other enteric diseases, and intestinal inflammation.
Presentation Topic: “A Four-pronged Threat: Clostridioides difficile Infection (CDI), Antibiotics, the Flu Season, and COVID-19.”
Maureen Spencer, RN, M.Ed. CIC
Maureen Spencer has been an Infection Preventionist for over 40 years and is board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing an MRSA and Staph aureus Elimination Program at New England Baptist Hospital, an Orthopedic Center of Excellence in Boston. The groundbreaking work was published in the Journal of Bone and Joint Surgery, Aug 2010. In 2012 she was selected as one of the “Who’s Who of Infection Prevention” and in 2017 she was recognized as a Fellow of the Association for Professionals in Infection Control and Epidemiology (FAPIC) for her advanced practice in infection prevention and leader within the field.
Presentation Topic: “Aerosol Transmission of Pathogens:
The Problem and the Solutions.”
GROUP DISCUSSION II
Paul Feuerstadt, MD, FACG, AGAF
Moderator – Group Discussion II
“2021 Guidelines: A path forward”?
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research, and graduated Summa Cum Laude. Following the completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency,
Stuart B. Johnson, MD, FIDSA, DTM&H
Panelist – Group Discussion II
Dr. Johnson, MD, FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus have involved the epidemiology pathogenesis and treatment of Clostridium difficile infection.
Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA
Panelist – Group Discussion II
Dr. Chopra, MD,MPH,FACP,FIDSA,FSHEA, an infectious disease specialist, Teena Chopra is a professor of internal medicine, infectious diseases, for the Wayne State University School of Medicine, as well as the corporate medical director of infection prevention and hospital epidemiology at the Detroit Medical Center. Chopra also serves on the Wayne State University Presidential Coronavirus Committee, assisting with preparations and response related to the virus.
Colleen Kelly, MD, FACG
Panelist – Group Discussion II
Dr. Kelly, MD, FACG, focus of her research and clinical practice is fecal microbiota transplantation (FMT) for the treatment of C. difficile infection (CDI). Dr. Kelly is currently one of the Principal Investigators for an NIH-funded FMT national registry which will answer important questions around real-world efficacy and safety of FMT and has assisted physicians and institutions around the country in developing FMT protocols. Dr. Kelly collaborates regionally, nationally and internationally with other physicians and scientists who have clinical and research interests in FMT.
Sabine Hazan, MD
Dr. Hazan, M.D., has over 22 years of experience in clinical trials and is the Founder and CEO at both Ventura Clinical Trials and Malibu Specialty Center. Dr. Hazan personally oversees clinical trials for high-profile studies on diseases such as Hepatitis C, Hypercholesterolemia, and Pancreatic Cancer. Physician, CEO of Progenabiome and Ventura Clinical Trials, Co-founder of Topelia Therapeutics; Expert on the Gut Flora (Microbiome) and cutting-edge medical research; Writer, Editor, World-Renowned Speaker, Published Author of “Let’s Talk Sh!t”
MD: University of Miami, Residency: Jackson Memorial Hospital, Fellowship: University of Florida
As a specialist in gastroenterology, internal medicine, and hepatology.
Presentation Topic: TBA
Dale Gerding, MD, MACP, FIDSA, FSHEA
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. Before his present position,
Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA), and past chair of the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDS
Presentation Topic: “Adjunctive Therapy for CDI to Prevent Recurrence: Practical Issues”.
Glenn Tillotson, Ph.D.
Dr. Tillotson has over 30 years of experience in global infectious disease and with a focus in anti-infective drug development and medical education, and medical affairs. Demonstrated capabilities in broad-ranging educational initiatives aimed at improving patient health. Dr. Tillotson has published multiple publications and an e-book on C difficile. Recently he has been active in developing new products for Clostridioides difficile, MRSA, and MDR Gram-negative infections. Built and led a medical affairs team to prepare for the approval and launch of a fourth-generation macrolide for use in pneumonia. Most recently played a role in the approval of cefiderocol, a novel siderophore cephalosporin, in the USA.
Presentation Topic: “Antimicrobial Stewardship and It’s Impact on C difficile.”
Carlene Muto, MD, MS, FSHEA
Dr. Muto, MD, MS, FSHEA, is an infectious disease physician and has been a hospital epidemiologist for more than 2 decades. She served as the Medical Director of Infection Control and Hospital Epidemiology at the University of Pittsburgh Health System for 17 years where she led infection prevention programs across at the health system. In 2016, she transitioned back to the Division of Infectious Diseases/Hospital Epidemiology at the University of Virginia. She holds a Master of Science in Epidemiology and has participated in many patient safety committees locally and nationally. Her research interests have focused on reduction/elimination of healthcare-associated infections (HAIs), with special emphasis on multidrug resistant bacteria and Clostridioides difficile, device related infections, and the effects of disinfection/sterilization on environmental related HAIs related to surfaces, endoscopes (CRE/MDROs), water (legionella), and linen (fungal infections). She recently became the Senior Medical Director of Clinical Effectiveness at Einstein Health Network.
Presentation Topic: “Clostridioides difficile, an Unforgiving Pathogen and a Pain In the Butt.”
We extend our gratitude to each sponsor who make this annual event possible.
To learn more about the Sponsors, please click on the graphics displayed below AND Visit http://www.cdiff2021.com for more details. Thank you.
- Poster: Heidi Hau PhD, Director Translational Biology Rebiotix Inc, a Ferring Company
- Title: “Treatment Success in Reducing Clostridioides difficile infection with Investigational Live Biotherapeutic RBX2660 as Associated with Microbiota Restoration: consistent Evidence from a Phase 3 Clinical Trial.”